Amarin Corp Plc (AMRN)

[ziploc_1]

Nsleven...QUOTE..."the 2007(teva) release included Coreg®’s total revenue, demonstrating Teva still intended to capture the entire heart failure market. In fact, Teva included heart failure revenue despite personnel explicitly questioning whether it was right to do so."

This paragraph is reminiscent of the Hikma strategy after the invalidation of the high triglyceride patent but with the Reduce-It patent still in tact...As I recall, Hickma predicted at a medical meeting that that they expected prospects for marketing gV would be a million prescriptions a year....an outcome which could only be achieved if Hickma added the 7% of the gV Rx's, which were prescribed for the high trig indication to the 93% gV Rx's, which were prescribed for the CVD indication.